Short answer
TransMedics Group, Inc. (TMDX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results covered quarter ended June 30, 2026.
TransMedics Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results covered quarter ended June 30, 2026
- Results announced August 4, 2026 through Exhibit 99.1 press release
- Disclosure furnished under Item 2.02, limiting Exchange Act Section 18 liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $189.9M, up 21%, led by service revenue growth of 29% to $78.8M
- GAAP operating margin fell to 12.5% from 23.2% as operating expenses rose 49% to $89.5M
- Net income declined 58% to $14.7M, or $0.41 diluted EPS, despite continued revenue growth
- 2026 revenue guidance raised to $737M-$757M, excluding PAD Aviation and incremental clinical-trial revenue
- PAD Aviation investment expands TransMedics’ planned European organ-logistics network, adding execution and capital-investment exposure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TransMedics Group, Inc. 8-K filings
Get the next TMDX 8-K as it lands
Follow TMDX for push alerts, or ask the research agent what this filing means.